Nalmefene versus butorphanol for prevention of intrathecal morphine-induced pruritus after cesarean delivery:a multicenter, randomized, controlled trial

Nalmefene versus butorphanol for prevention of intrathecal morphine-induced pruritus after cesarean delivery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900022268

Enrollment

Unknown

Registered

2019-04-02

Start date

2019-06-01

Completion date

Unknown

Last updated

2019-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prevention of intrathecal morphine-induced pruritus

Interventions

N group:0.2ug/kg Nalmefene

B group:0.02mg/kg butorphanol

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: ASA physical status I or II parturients, undergoing a cesarean delivery under spinal anesthesia

Exclusion criteria

Exclusion criteria: Major systemic disease, allergies to any medication included in the study protocol, and those with pre-existing pruritus due to pregnancy or a coexisting skin disorder or other pruritogenic systemic diseases.

Design outcomes

Primary

Measure	Time frame
Pruritus;	—

Secondary

Measure	Time frame
pain;Nausea and vomiting;	—

Countries

China

Contacts

Public ContactChaochao Zhong

Deparment of Anesthesiology, the Affiliated Hospital of Nantong University

zhong249767626@163.com+86 15152460489

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026